Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
De Roock, Wendy × Jonker, Derek J Di Nicolantonio, Federica Sartore-Bianchi, Andrea Tu, Dongsheng Siena, Salvatore Lamba, Simona Arena, Sabrina Frattini, Milo Piessevaux, Hubert Van Cutsem, Eric O'Callaghan, Chris J Khambata-Ford, Shirin Zalcberg, John R Simes, John Karapetis, Christos S Bardelli, Alberto Tejpar, Sabine #
Amer medical assoc
Journal of the American Medical Association vol:304 issue:16 pages:1812-1820
Context Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab.